Acknowledgement to Referees
The Diversity of Biosimilar Design and Development: Implications for Policies and Stakeholders
Classification of Recombinant Biologics in the EU: Divergence Between National Pharmacovigilance Centers
A Randomized, Phase I Pharmacokinetic Study Comparing SB2 and Infliximab Reference Product (Remicade®) in Healthy Subjects
Register-Based Evaluation of Relative Effectiveness of New Therapies: Biologics Versus Conventional Agents in Treatment of Psoriasis in Sweden
Siltuximab: A Review in Idiopathic (Human Herpesvirus-8-Negative) Multicentric Castleman Disease
Dulaglutide: A Review in Type 2 Diabetes